Stocks · Archetype
Event-driven · 238 research notes
Stocks classified as Event-driven: 238 stocks, each with a dated research note: thesis, kill line and next catalyst.
All 238 have a dated research note with a published kill line: the note's own test, stated in advance, of what would prove it wrong: a price level, a business fact, or both.
All stocksCHYMChime FinancialMedium Chime Financial's revenue growth sped up to 32% and its 2026 outlook rose a third time, giving the shares a modest edge over the S&P 500 over three months; the fourth-quarter 2026 report, against a $757–767 million forecast, settles it.CDNACareDxMedium CareDx's shares are modestly more likely than not to beat the S&P 500: transplant testing revenue grew 39% in the third quarter excluding catch-up collections and 2026 guidance rose to $520–530 million. CMS's final 2027 Medicare rates, due…CHAChagee HoldingsMedium Chagee Holdings is modestly more likely to lead the S&P 500 over three months: its shares cleared $14.00 on a $1.95 special dividend. The third-quarter report, expected around 27 November 2026, shows whether China same-store sales, down…ELFe.l.f. BeautyMedium e.l.f. Beauty's shares are modestly more likely than not to beat the S&P 500 because the company raised its fiscal 2027 organic sales growth outlook to 9%–11% after 51% quarterly sales growth. The fiscal third-quarter report, expected…EVHEvolent HealthMedium Evolent Health's margin repair now has evidence: Q3 medical costs fell to 93.0% of revenue and 2026 adjusted EBITDA guidance rose to $130–135 million. The late-February Q4 report, with its 2027 range, decides whether the $150 million-plus…GPNGlobal PaymentsMedium Global Payments trades on a reported $40 billion CD&R and GTCR buyout, and nine brokers raised targets after in-line third-quarter results on 5 November 2026; a signed deal at a premium, or word that talks have ended, settles the case.HUMHumanaMedium Humana's third-quarter cost beat and higher $9.50 adjusted EPS floor, reported 6 November 2026, make its shares modestly more likely than not to beat the S&P 500 as the Star Ratings recovery lifts 2028 margins. The 10 December investor…IRONDisc MedicineMedium Disc Medicine's shares are modestly favoured to beat the S&P 500 over three months because bitopertin passed its Phase 3 APOLLO trial on 19 October 2026, answering the FDA's February rejection. ASH pipeline data from 12 December 2026 and…MANEVeradermicsMedium Veradermics' hair-loss pill VDPHL01 has finished its male trials with clean 12-month safety and cash of $798.4M guided into 2030. The case now turns on when the company sets a new drug application date, with its 19 November 2026 Jefferies…ODDODDITY TechMedium ODDITY Tech's third-quarter beat and raised 2026 outlook back a recovery built on steady IL MAKIAGE repeat orders and a growing SpoiledChild. The fourth-quarter report, expected in late February 2027, shows whether the advertising-partner…ONTOnterrisMedium Onterris's shares trade on a board-led strategic review that has engaged outside buyers and on a third-quarter cash flow recovery; a review outcome and fourth-quarter operating cash flow against the $30.0M–$40.0M guide settle the case.ORKAOruka TherapeuticsMedium Oruka Therapeutics is modestly more likely to beat the S&P 500 over three months: its psoriasis antibody ORKA-001 cleared skin completely in 61% of high-dose patients against 0% on placebo, and the December 2026 52-week EVERLAST-A data…PVLAPalvella TherapeuticsMedium Palvella Therapeutics has pulled back from its record close while the FDA reviews QTORIN rapamycin for a 28 February 2027 decision, with no adverse review news and $236.7 million in cash; review updates and the fourth-quarter Phase 3 start…SMMTSummit TherapeuticsMedium Summit Therapeutics' case rests on FDA approval of ivonescimab in EGFR-mutant lung cancer by the 14 November 2026 goal date. The agency's reading of a primary survival result with p=0.057 settles it, and the shares closed at $15.07 on 12…XNCRXencorMedium Xencor's shares hold a modest edge over the S&P 500 on XmAb819's 45.5% confirmed response rate in advanced kidney cancer and cash funding into 2029. First-half 2027 data in at least 20 patients at 400 mcg/kg and the FDA's view on…ZLABZai LabMedium Zai Lab's shares are modestly more likely to beat the S&P 500 over three months on zoci, its DLL3 cancer drug with an 81.8% first-line response rate; a global first-line Phase 3 start announced by 31 December 2026 settles it.ZVRAZevra TherapeuticsMedium Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026 and the company is profitable; the EMA re-examination of arimoclomol, guided to the fourth quarter,…ABCLAbCellera BiologicsLow AbCellera's shares look more likely to lag the S&P 500 over three months, because the case rests on unproven repeat dosing of ABCL635, its monthly hot-flash injectable. The open-label extension data, guided for late 2026 to early 2027,…ADTLow ADT Inc. trades as a pending $10.00-per-share cash buyout by Thrive Holdings, so its shares are more likely to lag the S&P 500 than lead it. A rival bid before the go-shop window closes on 28 November 2026 is the one event that would…BACBank of AmericaLow Bank of America's shares look more likely to lag the S&P 500 as weak fees and trading, a $1.2 billion penalty and falling broker targets outweigh 8% lending-income growth; the 15 January 2027 fourth-quarter report shows whether fees…BMBLBumbleLow Bumble's shares are likely to trail the S&P 500 because they trade as a pending $6.05-per-share cash takeover by Ithaca Holdings, closing at $5.99 on 11 November 2026. Antitrust clearance and the Schedule 14C closing timeline decide when…BRZEBrazeLow Salesforce's agreed $47.50-per-share cash takeover of Braze caps the shares just under the offer, so they are more likely to lag the S&P 500 than lead it over three months. The US antitrust review, the stockholder vote or a rival bid…CAPRCapricor TherapeuticsLow Capricor Therapeutics' shares are more likely to lag the S&P 500 because deramiocel's approval faces an FDA panel that voted 9-3 against its evidence in July 2026. The FDA's action on the narrowed application, due by 22 November 2026,…CARTMaplebearLow Maplebear, Instacart's parent, looks likely to lag the S&P 500 because DoorDash's $65.00-a-share offer caps the gain while antitrust review may run into 2028. The first federal step on the merger filing settles the case.CRSPCRISPR TherapeuticsLow CRISPR Therapeutics shares are more likely to lag the S&P 500 over three months: they hit a 52-week closing low of $42.62 on 12 November 2026 despite strong CTX310 data, and December's zugo-cel data at ASH is the next test.CTVACortevaLow Corteva, now a pure crop-protection company, is more likely to lag the S&P 500 after cutting its 2026 profit outlook on 11 November 2026 over a materially weaker Brazil. The early-2027 fourth-quarter report and the first 2027 outlook show…DXCDXC TechnologyLow DXC Technology's shares are more likely to lag the S&P 500 because they trade above every post-results analyst target while the insurance-unit sale remains unsigned. A signed deal and its price settle the case.FRMIFermiLow Fermi Inc. shares are more likely to lag the S&P 500 over three months: a $200 million hyperscaler prepayment gives Project Matador a customer, but the 600-megawatt lease is unsigned and the 12 November 2026 10-Q flags going-concern doubt.…FRVOFervo EnergyLow Fervo Energy shares look more likely to lag the S&P 500 over three months: IPO lock-up supply and broker target cuts outweigh an $11.9 billion backlog. Cape Station's GeoBlocks 2 and 3 reaching commercial operation by 1 January 2027 decide…GRALGRAILLow GRAIL's shares are more likely to lag the S&P 500 over three months: after a 78.8% three-month rise, approval of the Galleri cancer test looks largely priced in while the company cut its 2026 Galleri revenue outlook and per-test prices…HELEHelen of TroyLow Helen of Troy's shares are more likely to lag the S&P 500 because the $37.98 close on 11 November 2026 already tops Empower Brands' rejected $37.00 offer. A higher signed deal, or a stalemate at the report due around 8 January 2027,…IBRXImmunityBioLow ImmunityBio's third-quarter Anktiva revenue of $48.7 million fell below the second quarter's $50.7 million, and the shares are more likely to lag the S&P 500 until detailed QUILT-2.005 efficacy data and a fourth-quarter revenue rebound…KODKodiak SciencesLow Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share sales have begun. The PEAK topline, guided for December 2026, settles it.LITELumentum HoldingsLow Lumentum Holdings' shares look more likely to lag the S&P 500 because a fixed 4.500-share Marvell merger ties them to Marvell's stock more than to Lumentum's growth. Marvell's 1 December 2026 quarterly report is the next test.OPCHOption Care HealthLow Option Care Health's $32.05-per-share cash sale to CD&R and McKesson caps the shares, which closed at $31.70 on 11 November 2026, so they are more likely to lag than lead the S&P 500. The 3 December 2026 antitrust waiting-period expiry and…PCRXPacira BioSciencesLow Pacira BioSciences trades as a pending takeover pinned near Viatris's $36.50 cash offer, so the shares are more likely to lag the S&P 500 than lead it. The tender offer expiring on 16 November 2026, with antitrust clearance already…PSNLPersonalisLow Personalis trades as a fixed $16.25-per-share claim on Tempus AI's agreed takeover, so the shares are more likely to lag the S&P 500 than lead it; the 30 November 2026 stockholder vote and the closing settle it.PTCLow PTC Inc. is pinned just below Schneider Electric's $205-per-share cash offer, which the buyer called best and final, so the shares are more likely to lag the S&P 500 than lead it. Antitrust and CFIUS reviews, the shareholder vote and a…QDELQuidelOrthoLow QuidelOrtho's shares are more likely to lag the S&P 500: third-quarter revenue fell 11.6% and net leverage rose to 4.5 times while the point-of-care sale meant to cut $2.94B of borrowings is still unsigned. A signed deal or the…RRCRange ResourcesLow Range Resources is likely to lag the S&P 500 because its shares now trade as 0.987 EQT shares under EQT's all-stock takeover, with the premium priced in; EQT's share price, gas prices and the shareholder votes before a first-quarter 2027…RXOLow RXO, Inc. is likely to lag the S&P 500 because C.H. Robinson's pending $17.25-cash-plus-0.0856-share takeover caps its upside. Antitrust review, the registration statement and the shareholder vote settle the deal, with closing targeted for…SGRYSurgery PartnersLow Surgery Partners' shares, at $26.58 on 12 November 2026, already price in more than HealthSpan Partners' $25.00 cash deal pays and are more likely to lag the S&P 500. Whether the rejected $28.00 bidder, reported to be UnitedHealth, returns…SLNSilence TherapeuticsLow Silence Therapeutics' shares trade just under Merck KGaA's $20-per-ADS cash takeover price, so they are more likely to lag the S&P 500 than lead it over three months. The proxy statement that dates the scheme vote, and antitrust clearance…SLSSELLAS Life Sciences GroupLow SELLAS Life Sciences is more likely to lag the S&P 500 over three months: its value rests on one Phase 3 leukemia trial, REGAL, whose topline survival result the company said on 12 November 2026 it expects this month, and the shares closed…SMRNuScale PowerLow NuScale Power's shares are more likely to lag the S&P 500 because the binding ENTRA1–TVA power purchase agreement its case needs is still unsigned and undated. A signed agreement, or none by year-end 2026, settles the case.TET1 EnergyLow T1 Energy's shares are more likely to lag the S&P 500 over three months because its G2_Austin cell plant still lacks closed financing and unrestricted cash was $59.5 million at 30 September 2026; a financing close, targeted by year-end…ULCCFrontier Group HoldingsLow Frontier Group Holdings (Frontier Airlines) shares are more likely to lag the S&P 500: a $7.70 close on 12 November 2026 sits above most post-report targets as officers sold stock. The early-2027 fourth-quarter report settles whether…VALValarisLow Valaris shares are more likely to lag the S&P 500 because they trade as Transocean stock at 15.235 shares each, and Transocean's 2 November 2026 results showed lower revenue and a flat 2027 outlook. The 24 November 2026 votes, the 26…VKTXViking TherapeuticsLow Viking Therapeutics is more likely to lag the S&P 500 over three months: $960 million in cash funds its obesity Phase 3 trials, but no pivotal efficacy result is scheduled before 2027. The ObesityWeek posters from 15 November 2026 add…WINGWingstopLow Wingstop's shares have run ahead of its business and are more likely to lag the S&P 500: they rose 46.8% in three months to $166.73 on 11 November 2026 despite a third cut to same-store-sales guidance. The fourth-quarter report, expected…ABVXAbivax SAMedium Abivax's shares are modestly more likely to beat the S&P 500 over three months because the company guides its US obefazimod ulcerative colitis marketing application to the fourth quarter of 2026; a filing by 31 December 2026 settles it.ACBAurora CannabisMedium Organigram Global's agreed C$7.80-per-share deal sets the value for Aurora Cannabis, whose shares trade below it; Curaleaf's response before its offer expires on 4 December 2026 and December shareholder votes settle whether holders get…ACLSAxcelis TechnologiesMedium Axcelis Technologies guided fourth-quarter 2026 revenue to about $275 million, far above the $238.8 million analyst estimate, which makes the shares modestly more likely than not to beat the S&P 500 over three months; gross margin and…BHVNBiohavenMedium Biohaven Ltd. is modestly more likely than not to beat the S&P 500 over three months: the SK Biopharmaceuticals licence has cleared US antitrust, and receipt of its $350 million payment plus the second-half 2026 RISE3 epilepsy readout…CLOVClover Health InvestmentsMedium Clover Health's profit is rising with Medicare Advantage membership, and the 4 November 2026 quarter lifted full-year guidance; the CMS appeal of the court-ordered Star Rating remains the event that can reverse the gains.CLYMClimb BioMedium Climb Bio's budoprutug showed a clear antibody effect in membranous nephropathy and the third-quarter report kept funding into the second half of 2028; the December 2026 ASH immune thrombocytopenia data test whether the drug works beyond…CMGChipotle Mexican GrillMedium Chipotle Mexican Grill's customer traffic is growing again (third-quarter transactions +0.8%, comparable sales +2.1%), which modestly favors the shares over the S&P 500; the fourth-quarter report in early 2027 settles whether margins stop…CMPSCOMPASS PathwaysMedium Compass Pathways is modestly more likely to beat the S&P 500 over three months: its COMP360 psilocybin filing was completed on 9 November 2026 under a one-to-two-month voucher review target, and FDA acceptance and an action date decide…CNCCenteneMedium Centene is more likely to beat the S&P 500 over three months: its raised 2026 adjusted EPS guidance of more than $5.20 shows medical costs improving. The fourth-quarter report, expected in February 2027, settles whether it holds.CORTCorcept TherapeuticsMedium Corcept Therapeutics' Lifyorli launch is compounding ($91.4 million in Q3 2026, up from $47.6 million in Q2), yet the shares sit near their 200-day average on an unchanged $1.1–$1.2 billion revenue guide; the 17 December 2026 FDA decision…ELVNEnliven TherapeuticsMedium Enliven Therapeutics is modestly more likely than not to beat the S&P 500 over three months: $884.4 million in cash and FDA alignment fund ENABLE-2, its pivotal leukemia trial, and a disclosed first patient before year-end 2026 would…EVGOMedium EVgo's shares track majority owner LS Power's $2.00-per-share cash take-private offer and closed at $1.75 on 12 November 2026, below it. The special committee's answer settles the case: a signed deal at $2.00 closes the gap, while a…EXTRExtreme NetworksMedium Extreme Networks pairs a beat-and-raise operating quarter with a Reuters-reported sale process; a named bidder or offer settles the takeover case, and second-quarter fiscal 2027 revenue against the $345.8–350.8 million guide settles the…IMVTImmunovantMedium Immunovant's 9 November 2026 rheumatoid arthritis win at the 600 mg dose of IMVT-1402 makes the shares modestly more likely than not to beat the S&P 500 over three months; FDA feedback on a registrational path, guided for late 2026 or…JBIOJade BiosciencesMedium Jade Biosciences' IgA nephropathy antibody JADE101 is funded into the fourth quarter of 2028, which leaves the shares modestly likelier than not to beat the S&P 500 over three months; the EVERGREEN Phase 3 start guided for the fourth…LRMRLarimar TherapeuticsMedium Larimar Therapeutics is modestly more likely than not to lead the S&P 500 over three months: it finished its nomlabofusp filing on 9 November 2026 and seven insiders bought shares on 11 November 2026 and 12 November 2026. The FDA's filing…LYELLyell ImmunopharmaMedium Lyell Immunopharma's ronde-cel is posting response rates strong enough to support a planned 2027 approval filing, with a 91% response rate in 44 pivotal-trial patients and funding into 2028. The December 2026 ASH presentations are the next…MBXMBX BiosciencesMedium MBX Biosciences is modestly more likely than not to beat the S&P 500 over three months: $481.6 million of cash funds canvuparatide into 2029, and the 12-week MBX-4291 obesity data guided for the fourth quarter of 2026 settle the second…MIRMMirum PharmaceuticalsMedium Mirum Pharmaceuticals is modestly more likely than not to lead the S&P 500 over three months: both Phase 3 hepatitis delta studies are positive and LIVMARLI sales are growing. The report expected around 25 February 2027 tests the $715–720…OSCROscar HealthMedium Oscar Health is modestly likely to beat the S&P 500: it raised 2026 earnings-from-operations guidance to $850–950 million on 5 November 2026 and is expanding for 2027. Open-enrollment results and the fourth-quarter report settle it.PESIPerma-Fix Environmental ServicesMedium Perma-Fix Environmental Services met the revenue test in its 5 November 2026 report, with $17.948 million against $12.885 million in Q2, but treatment still lost money and going-concern doubt remains. The first Hanford task order decides…PIImpinjMedium Impinj's third-quarter report confirmed the RFID recovery: record revenue of $112.1M and a fourth-quarter revenue guide above consensus. Margins are guided lower, so the next report, expected in late February 2027, decides whether profit…PLSEPulse BiosciencesMedium Pulse Biosciences is modestly more likely to lead the S&P 500 because $189.2 million of cash funds its atrial-fibrillation catheter through pivotal follow-up. The persistent-AF study filing guided for the fourth quarter of 2026 and…PRMPerimeter SolutionsMedium Perimeter Group (formerly Perimeter Solutions) is modestly more likely than not to beat the S&P 500 over three months: Fire Safety profit grew 14% in the third quarter. The fourth-quarter report, expected around 26 February 2027, tests it.QUITAchieve Life SciencesMedium AchieveRx (formerly Achieve Life Sciences) is modestly more likely than not to beat the S&P 500 over three months if its cytisinicline resubmission to the FDA lands in the fourth quarter of 2026; the refiling, due by about 31 December…RIVNRivian AutomotiveMedium Rivian Automotive is modestly more likely than not to beat the S&P 500 over three months: R2 volume and raised guidance support the case, and the Q4 report, expected in February 2027, settles whether automotive gross margin turns positive.…RLAYRelay TherapeuticsMedium Relay Therapeutics' value rests on zovegalisib, and its 4 November 2026 quarterly report moved the case forward: $848.6 million of cash funds operations into 2029, and breast-cancer trial enrollment is guided to finish in mid-2027. The 14…RZLTRezoluteMedium Rezolute's ersodetug rests on the tumor hyperinsulinism upLIFT study, with topline guided to mid-December 2026; the final responder rate against the 7-of-8 interim settles it, and a $400 million registration filed 5 November 2026 raises…TVTXTravere TherapeuticsMedium Travere Therapeutics' FILSPARI kidney-drug sales beat the third-quarter benchmark at $200.2 million, but new patient start forms slipped to 1,932 and Q4 carries an inventory drag. Fourth-quarter sales and the 1 December CEO handover decide…UIUbiquitiMedium Ubiquiti's record $1,026.2M quarter and 47.3% gross margin support the case; the February report settles whether margin survives rising component costs.VIRVir BiotechnologyMedium Vir Biotechnology's hepatitis delta regimen met its pivotal ECLIPSE 1 endpoint on 8 November 2026 (44% response versus 0%), so the shares lean toward beating the S&P 500 over three months despite the new stock offering. The ECLIPSE 2 and 3…WDAYWorkdayMedium Workday's shares are modestly more likely to beat the S&P 500 over three months: a slowing but intact subscription business plus an unconfirmed Silver Lake takeover premium. Results on 24 November 2026 show whether cRPO growth lands inside…ZBIOZenas BioPharmaMedium Zenas BioPharma is modestly more likely than not to beat the S&P 500 over three months; the SunStone Phase 2 lupus result for obexelimab, guided for the fourth quarter of 2026, settles whether the drug reaches beyond IgG4-RD.ZYMEZymeworksMedium Zymeworks shares have a modest edge over the S&P 500 after the company raised 2026 revenue guidance to $337–351 million on 9 November 2026; Roche antitrust clearance, expected in Q4 2026, and Jazz's next Ziihera sales report settle it.ABEOAbeona TherapeuticsLow Abeona Therapeutics' ZEVASKYN revenue grew 18% to $13.5 million in the third quarter but missed estimates, and a $3.75-a-share placement plus a stock-funded drug purchase left the shares at $2.30; they are more likely to lag the S&P 500.ABSIAbsciLow Absci Corporation's shares are more likely to lag the S&P 500 over three months because the price still assumes a hair-loss win for ABS-201; the 13-week interim data guided for December 2026 settle it.AGIOAgios PharmaceuticalsLow Agios Pharmaceuticals' shares are more likely to lag the S&P 500 until the FDA rules on mitapivat in sickle cell disease by 1 February 2027; thalassemia sales are growing, but new prescriptions are slowing and a safety program is possible.AGLTChurchill Capital Corp XILow Agility Robotics (AGLT), the humanoid-robot maker listed via its 4 November 2026 merger with Churchill Capital Corp XI, is more likely to lag the S&P 500: revenue is small, and resale of about two-thirds of shares is registered.AIROAIRO Group HoldingsLow AIRO Group Holdings is more likely to lag the S&P 500: it beat third-quarter 2026 revenue estimates and lifted backlog to about $200 million, but moved full-year growth to the low end and cash fell to $37.8 million. The fourth-quarter…AKTSAktis OncologyLow Aktis Oncology's shares are more likely to lag the S&P 500 over three months: its lead radiopharmaceutical AKY-1189 has no efficacy data, and preliminary NECTINIUM-2 results, guided for the first quarter of 2027, settle the case.ALHCAlignment HealthcareLow Alignment Healthcare's 29 October 2026 cut to full-year profit guidance makes the shares more likely to lag the S&P 500 over three months; the fourth-quarter report, expected around February 2027, shows whether medical costs are turning.ALMSAlumisLow Alumis, a one-drug psoriasis company, is more likely to lag the S&P 500 over three months: cash fell to $431.3 million and lupus has no funded path. The envudeucitinib NDA filing guided for the quarter ending 31 December 2026 settles it.ALVOAlvotechLow Alvotech's shares are more likely to lag the S&P 500 because cash fell to $61.5 million at 30 September 2026 and 2026 revenue is now guided to the low end. FDA decisions on its Simponi and Eylea biosimilars, AVT05 and AVT06, expected in Q4…AMBAAmbarellaLow Ambarella's shares are more likely to lag the S&P 500 over three months: they sit below their 50-day and 200-day averages and the reported NXP sale talks have not lifted them; the third-quarter fiscal 2027 report on 24 November 2026…AMLXAmylyx PharmaceuticalsLow Amylyx Pharmaceuticals' shares are more likely to lag the S&P 500 because avexitide's Phase 3 win and $768.1 million of cash are already public, and the stock sits below the $35.50 August offering price. The 15 November 2026 full LUCIDITY…ANABAnaptysBioLow AnaptysBio's shares are more likely to lag the S&P 500 over three months because their value rests on an undated Delaware Chancery judgment on returning Jemperli rights from GSK's Tesaro unit, expected in the fourth quarter of 2026 or the…ANROAlto NeuroscienceLow Alto Neuroscience's depression program is funded through 2030 on company guidance, and the 10 November 2026 report left every timeline intact, but the shares have rallied hard with no efficacy data until 1H 2027 and are more likely to lag…AQSTAquestive TherapeuticsLow Aquestive Therapeutics' shares lean toward lagging the S&P 500 over three months: the FDA decision on its needle-free epinephrine film Anaphylm falls on 16 March 2027, after the window, and third-quarter revenue of $7.6 million missed…ARCTArcturus Therapeutics HoldingsLow Arcturus Therapeutics has cash into 2028 but no dated FDA path for ARCT-810 and no dated Phase 3 decision for ARCT-032, so the shares are more likely to lag the S&P 500 until the company sets those dates.ARTVArtiva BiotherapeuticsLow Artiva Biotherapeutics is more likely to lag the S&P 500 over three months: its $319.1 million of cash depends on a board strategic review with no set date, and the shares have no scheduled event to settle it.ARXAccelerant HoldingsLow Accelerant Holdings is more likely to lag the S&P 500 over three months: Thoma Bravo's $20.25 per share cash offer caps the upside from the $19.89 close on 12 November 2026. Regulatory approvals and the shareholder vote settle whether the…ASMBAssembly BiosciencesLow Assembly Biosciences is more likely to lag the S&P 500 over three months: the shares closed at $20.18 on 12 November 2026, down 38.8% in three months, and Gilead's GS-1179 Phase 2 start, due by 31 December 2026, settles whether the case…AVLNAvalyn PharmaLow Avalyn Pharma's shares are more likely to lag the S&P 500 over three months: the inhaled-antifibrotic case has no efficacy data until the MIST Phase 2b readout in the second half of 2027, and the 18 November 2026 conference update is the…AVTXAvalo TherapeuticsLow Avalo Therapeutics' abdakibart keeps a funded Phase 3 plan in hidradenitis suppurativa, but the shares sit near $7 after AbbVie's rival data; FDA feedback on the Phase 3 design, guided for H2 2026, settles the case.AVXLAnavex Life SciencesLow Anavex Life Sciences is more likely to lag the S&P 500: the shares hit a 52-week closing low of $1.06 on 11 November 2026 after three directors quit. The FDA's Rett pediatric meeting and the fiscal year-end report settle whether the slide…BAKBraskemLow Braskem's creditor talks have no agreement and shareholders withdrew their funding offer on 6 November 2026, so heavy dilution for the listed ADR is likelier than a clean deal; the creditor-support deadline of about 22 November 2026…BBNXBeta BionicsLow Beta Bionics' shares are more likely to lag the S&P 500 while iLet buyers wait for the Mint patch pump's Q1 2027 launch; Mint shipments and coverage at the early-2027 report settle it.BCAXBicara TherapeuticsLow Bicara Therapeutics' shares are more likely to lag the S&P 500 because Genmab's rival head-and-neck drug won a Phase 3 trial and Bicara's own randomized data arrive only in mid-2027. Full FORTIFI-HN01 enrollment and $442.3 million of cash,…BIOABioAge LabsLow BioAge Labs' shares are more likely to lag the S&P 500 than lead it until the QUELL-CV hsCRP topline for BGE-102, guided to the fourth quarter of 2026, shows whether Phase 1 biomarker results hold against placebo.BLSHBullishLow Bullish's shares are more likely to lag the S&P 500 over the next three months: October trading volume fell to $37.7 billion and no issuer has committed to tokenization. The 18 November 2026 third-quarter report settles whether revenue…BMEABiomea FusionLow Biomea Fusion is more likely to lag the S&P 500 over three months: cash fell to $26.8 million at 30 September 2026 and BMF-650 has no partner; the 16 November 2026 ObesityWeek poster and any financing news settle it.BOLDBoundless BioLow Boundless Bio is more likely to lag the S&P 500 over three months: the Serapha Bio deal offers a $44–48 million cash dividend plus about 3.8% of the combined company. The 3 December 2026 shareholder vote and a per-share declaration settle…BVSBioventusLow Bioventus's shares depend on its strategic review ending in a sale, and the 2 November 2026 cut to 2026 sales guidance weakens the standalone fallback; a signed deal or an end-of-review notice settles it, and the shares are more likely to…BWINBaldwin Insurance GroupLow The Baldwin Insurance Group is a signed $32.50 cash take-private, so its shares are capped near the deal price and likely to lag the S&P 500; the shareholder vote, antitrust clearance and buyout financing for a first-quarter 2027 close…CABACabaletta BioLow Cabaletta Bio's rese-cel CAR-T program is more likely to lag the S&P 500 over three months: registrational myositis results slipped to the second half of 2027, and the shares closed at $1.33 on 12 November 2026, near their $1.28 closing…CADLCandel TherapeuticsLow Candel Therapeutics' shares are more likely to lag the S&P 500 over three months: on 12 November 2026 the company pushed its prostate-cancer BLA from the fourth quarter of 2026 to mid-2027, and a filing earlier than that would show the…CCCCCC Intelligent Solutions HoldingsLow CCC Intelligent Solutions' $7.75-per-share cash sale to a GTCR-led group including Elliott caps the shares near the offer, so they are more likely to lag the S&P 500; closing, expected in the first quarter of 2027, settles the case.CGCCanopy GrowthLow Canopy Growth's cash burn and international sales improved in the quarter reported 6 November 2026, yet the shares closed at $0.59 on 10 November 2026; the DEA judge's recommendation and a board decision on a share consolidation settle the…CGEMCullinan TherapeuticsLow Cullinan Therapeutics is more likely to lag the S&P 500 over three months: the shares closed at $10.19 on 12 November 2026, below both moving averages, even as the first-line zipalertinib filing was completed. The December CLN-978 data…CLDXCelldex TherapeuticsLow Celldex Therapeutics has two positive Phase 3 urticaria trials and cash guided through 2028, yet its shares closed at $30.15 on 11 November 2026, below both moving averages, and look more likely to lag the S&P 500. The late-2026 atopic…CNMDCONMEDLow CONMED Corporation's shares are more likely to lag the S&P 500 over three months: the price leans on an unconfirmed July sale report while the 28 October 2026 report trimmed organic growth guidance. A confirmed deal or the fourth-quarter…CRDLCardiol TherapeuticsLow Cardiol Therapeutics is more likely to lag the S&P 500 over three months: the MAVERIC Phase III topline is guided for mid-2027, and the company has begun selling stock under a US$75 million at-the-market program. That readout settles the…CRVSCorvus PharmaceuticalsLow Corvus Pharmaceuticals' soquelitinib shares are more likely to lag the S&P 500 over three months: the Angel eczema readout slipped to March 2027, so the main test sits past the window. $202.9 million of cash funds trials into the second…CVICVR EnergyLow CVR Energy's shares are more likely to lag the S&P 500 over three months: the $4.2 billion Marathon refinery purchase rests on outside funding and refining margins have faded. Closing of the deal, expected by the end of 2026, settles it.DFTXDefinium TherapeuticsLow Definium Therapeutics shares are likely to lag the S&P 500: its 9 November 2026 report kept the DT120 filing on track for the first half of 2027, yet the shares fell after it. The undated fourth-quarter FDA pre-filing meeting settles the…DNTHDianthus TherapeuticsLow Dianthus Therapeutics' shares are more likely to lag the S&P 500 than lead it over three months, because the case rests on one binary event: the Phase 2 MoMeNtum readout of claseprubart in multifocal motor neuropathy, guided to December…DSGNDesign TherapeuticsLow Design Therapeutics' shares are more likely to lag the S&P 500: a new $200 million stock-sale program adds supply while DT-216P2's regulatory path is unconfirmed; the company's Q4 2026 registrational-plans update settles it.DSGRDistribution Solutions GroupLow Distribution Solutions Group's shares are more likely to lag the S&P 500 over three months: they trade on a $35.00 cash buyout from LKCM Headwater, which caps upside. The definitive proxy and the unaffiliated-holder vote, due before the 31…DTILPrecision BioSciencesLow Precision BioSciences' hepatitis B gene-editing data held up in full, but with no clinical result due before Phase 2 dosing in early 2027 the shares are more likely to lag the S&P 500. Year-end 2026 Duchenne safety data is the next dated…DYNDyne TherapeuticsLow Dyne Therapeutics' shares are more likely to lag the S&P 500 over three months: the case rests on the FDA's 21 January 2027 decision on zeleciment rostudirsen in Duchenne and the Q1 2027 myotonic dystrophy topline, with cash funded into Q2…EFXEquifaxLow Equifax shares are more likely to lag the S&P 500 over the next three months: the October rebound already prices in 8% non-mortgage growth, and FHFA's pending bi-merge ruling and the February 2027 guidance settle the case.EPCEdgewell Personal CareLow Edgewell Personal Care's shares are more likely to lag the S&P 500 over three months: the fiscal 2027 outlook sits on analyst estimates and the price is under a rejected $30 bid. The first fiscal 2027 quarterly report, expected around…EPRXEupraxia PharmaceuticalsLow Eupraxia Pharmaceuticals' once-a-year EoE steroid injection, EP-104GI, is priced on open-label data from 14 patients, and the shares have rallied into a 13 November 2026 Analyst Day. The December 2026 placebo-controlled Phase 2b interim…ERASErascaLow Erasca's pan-RAS drug ERAS-0015 faces a binary test in the 20 November 2026 oral presentation of more pancreatic cancer patients; with the Revolution Medicines patent dispute open, the shares are more likely to lag the S&P 500 than lead it.FDMT4D Molecular TherapeuticsLow 4D Molecular Therapeutics' gene therapy 4D-150 has no controlled efficacy data yet, so the shares are more likely to lag the S&P 500 until the randomized 4FRONT-1 wet AMD topline guided for the second quarter of 2027, while cash fell to…FIGFigmaLow Figma's revenue beat and raised guidance, but gross margin and net dollar retention both fell as AI credits got cheaper, so the shares are more likely to lag the S&P 500 over three months. The fourth-quarter report, expected around…FOURShift4 PaymentsLow Shift4 Payments' growth recovery stalled on 5 November 2026 (organic growth 9%, guidance cut again), so the shares are more likely to lag the S&P 500; the early-2027 fourth-quarter report decides whether record cash flow and buybacks carry…FRNMFreenomeLow Freenome's shares are rated more likely to lag the S&P 500: its 10 November 2026 report showed $430.0 million of cash, but $180.0 million of $183.5 million quarterly revenue was a one-off Abbott collaboration payment. The December 2026…GERNGeronLow Geron Corporation's case now rests on RYTELO in lower-risk MDS, which grew to $60.1 million in the third quarter, up about 27% on the year; the fourth-quarter report and stock-sale dilution at about $0.97 a share settle it.GHRSGH ResearchLow GH Research's shares are more likely to lag the S&P 500 over three months: they trade just above the $18.00 April 2026 offering price with no dated pivotal-trial start, and the third-quarter report, estimated for 20 November 2026, is the…GLUEMonte Rosa TherapeuticsLow Monte Rosa Therapeutics' Novartis milestones now fund its business, but the MRT-8102 heart-disease test, GFORCE-2, is guided only for H1 2027. Until it starts and reads out, shares trade on milestones, spending and start dates.GSHDGoosehead InsuranceLow Goosehead Insurance shares are more likely to lag the S&P 500 over three months: the company expects to report material weaknesses, its restated financials and third-quarter 10-Q are unfiled, and the amended filings settle the case.HELPCybinLow Helus Pharma (formerly Cybin) is more likely to lag the S&P 500 over three months: the shares rest on one Phase 3 depression trial, APPROACH, guided to report in the fourth quarter of 2026, and a miss or a slip past 31 December 2026…HOVHovnanian EnterprisesLow Hovnanian Enterprises' shares are more likely to lag the S&P 500: they closed at $98.01 on 11 November 2026, down 28.1% in three months, and the early-December fiscal fourth-quarter report decides whether backlog converts into guided…HPKHighPeak EnergyLow HighPeak Energy's shares are more likely to lag the S&P 500: a third-quarter beat came with a $55.7 million net loss on hedges, and free cash flow fell short of the quarter's debt payment. The refinancing closing, which the company expects…HROWHarrowLow Harrow, the eye-care drugmaker, is more likely to lag the S&P 500 over three months: it cut its 2026 adjusted profit outlook by more than half on 9 November 2026. The fourth-quarter results, due around March 2027, show whether revenue…HZOMarineMaxLow MarineMax trades as a pending $53.00-per-share cash takeover by Safe Harbor Marinas, which caps the shares near their price and makes them likelier to lag the S&P 500. The filed vote result and a closing on or after 7 December 2026 settle…IDYAIDEAYA BiosciencesLow IDEAYA Biosciences is more likely to lag the S&P 500: its Phase 3 OptimUM-010 trial closed on poor enrollment and brokers cut targets after the 3 November 2026 report. FDA acceptance of darovasertib and the IDE849 Phase 3 starts settle the…IHRTiHeartMediaLow iHeartMedia's shares are likely to lag the S&P 500 after it cut 2026 Adjusted EBITDA guidance to $550–600 million from about $800 million on 9 November 2026, with $4.68 billion of net debt; the fourth-quarter report in early 2027 shows…IKTInhibikase TherapeuticsLow Inhibikase Therapeutics' IKT-001 for pulmonary arterial hypertension is funded, with $193.3M cash on 30 September 2026, but dilution and warrant-dependent runway weigh on shares at $1.55; 2027 interim safety data is next.IMMXImmix BiopharmaLow Immix Biopharma's CAR-T therapy NXC-201 has strong interim data, but the shares are more likely to lag the S&P 500 while they trade below both 2026 offering prices; the 14 December 2026 ASH presentation settles whether the 89% response…IMRNImmuronLow Immuron Limited's strategic review, announced 10 November 2026 with LifeSci Capital, lifted shares to $0.93, but the company says no deal is assured; the shares are still more likely to lag the S&P 500 until terms are disclosed.IMRXImmuneeringLow Immuneering's atebimetinib is still a single-arm pancreatic-cancer story, and the randomized MAPKeeper 301 trial, guided to mid-2028, settles it. The third-quarter report moved cash runway to the fourth quarter of 2028, from 2029.INBXInhibrx BiosciencesLow Inhibrx Biosciences' head-and-neck drug ordastobart led pembrolizumab alone on response rate (48.3% vs 26.5%, 8 September 2026), but the shares are more likely to lag the S&P 500; the Q3 report's financing and Phase 3 timing settle it.INSPInspire Medical SystemsLow Inspire Medical Systems is more likely to lag the S&P 500 over three months: revenue fell 7.9% in the third quarter and 2026 guidance was only narrowed. The fourth-quarter report, expected around February 2027, settles whether the decline…INTRInterLow Inter & Co.'s shares are more likely to lag the S&P 500 over three months: profit grew 26% in the 12 November 2026 report, but late overdue loans rose to 5.3% and Brazilian rates and the real set the price. The fourth-quarter report,…IOVAIovance BiotherapeuticsLow Iovance Biotherapeutics' shares are more likely to lag the S&P 500 than lead it: a third-quarter Amtagvi sales beat on 5 November 2026 met an 11% one-day fall, and the lung case now rests on a biomarker subgroup. Full-year 2026 revenue…IRDMIridium CommunicationsLow Iridium Communications trades as a claim on Rocket Lab's $27.00 cash-plus-stock offer, so its upside is capped and the shares are more likely to lag the S&P 500; the FCC license-transfer decision and Rocket Lab's price against the $67.50…ITGRInteger HoldingsLow Integer Holdings' shares are more likely to lag the S&P 500 over three months: KKR's $127.00 cash price caps the gain. Completion, which the company targets by 31 December 2026, settles the outcome.ITUBItau Unibanco HoldingLow Itaú Unibanco still earns a 23.6% return on equity, in line with forecasts, but its US shares trade on Brazil's fiscal risk and sit at $7.39, level with 28 October 2026; the fourth-quarter report and Lula's economic team settle the case.IVAInventivaLow Inventiva's shares are more likely to lag the S&P 500 over three months: funding is conditional and the lanifibranor MASH result is a coin flip on a single asset. The undated fourth-quarter 2026 NATiV3 topline settles the call.JBHTJ.B. Hunt Transport ServicesLow J.B. Hunt's shares are more likely to lag the S&P 500 over three months: third-quarter operating income rose 2% on 20% revenue growth, and fuel-excluded intermodal pricing rose 2%. The 2027 contract bid season settles whether margins…JBLUJetBlue AirwaysLow JetBlue Airways is more likely to lag the S&P 500: lenders holding about 55% of its 2031 bonds and first-lien loan signed a cooperation pact on 11 November 2026, and $8.4 billion of debt meets $4.64-a-gallon fuel; financing news or…JOBYJoby AviationLow Joby Aviation's shares lean toward lagging the S&P 500 over three months: the third-quarter revenue beat is Blade air-charter income, and initial U.S. passenger operations moved to 2027. Dubai flight testing by year-end 2026 and FAA flight…KURAKura OncologyLow Kura Oncology's KOMZIFTI sales rose 53% to $13.9 million in the third quarter of 2026. Even so, a new shelf filing and a cut to 2026 collaboration-revenue guidance leave the shares more likely to lag the S&P 500, and ASH data in December…KYMRKymera TherapeuticsLow Kymera Therapeutics' shares are more likely to lag the S&P 500 because the price already reflects a clear win for oral eczema drug KT-621; the Phase 2b BROADEN2 topline, guided by year-end 2026, settles whether efficacy nears Dupixent's.LOVELovesacLow Lovesac's shares are more likely to lag the S&P 500 over three months after the 10 September 2026 guidance cut; the third-quarter report, expected around 10 December 2026, settles whether results hold inside the lowered guide.LSTRLandstar SystemLow Landstar System is more likely to lag the S&P 500 over three months: third-quarter truck revenue per load rose about 25%, but earnings of $1.42 per share missed on $21 million of claims costs, and Morgan Stanley cut its target to $130 on…MATMattelLow Mattel's 2026 guidance cut on 5 November 2026 leaves an unconfirmed Authentic Brands takeover approach as the main support for the shares, which look more likely to lag the S&P 500; a confirmed offer, a sale process or the February 2027…MAZEMaze TherapeuticsLow Maze Therapeutics' kidney drug MZE829 has an early efficacy signal and cash guided into 2029, but the shares are more likely to lag the S&P 500: full HORIZON data slipped to early 2027 and the shares have already rallied.MESOMesoblastLow Mesoblast's cell therapy Ryoncil grew 44% from a year earlier but fell to US$28 million from US$36 million in June, so the shares are more likely to lag the S&P 500; the report for the December 2026 quarter, due around January 2027,…MGNXMacroGenicsLow MacroGenics' B7-H3 cancer drug MGC026 showed head-and-neck responses, but shares are more likely to lag the S&P 500: third-quarter revenue fell to $18.7 million and the next MGC026 data is not due until mid-2027.MGTXMeiraGTx HoldingsLow MeiraGTx's shares are more likely to lag the S&P 500 over three months: the US filing for its gene therapy bota-vec slipped to the first quarter of 2027, and the December 2026 European submission is the next test.MKTXMarketAxess HoldingsLow MarketAxess Holdings' fixed $167 cash sale to Intercontinental Exchange caps the shares' upside, so they are more likely to lag the S&P 500 over three months; the remaining non-US approvals and the first-quarter 2027 closing settle it.MMYTMakeMyTripLow MakeMyTrip's shares rebounded to $51.60 on 10 November 2026 with no new results; 20.9% constant-currency bookings growth sits against a 2.5% revenue rise and falling air demand, and the late-January 2027 report settles it.MNPRMonopar TherapeuticsLow Monopar Therapeutics' Wilson disease drug ALXN1840 keeps an open FDA path, but the shares are more likely to lag the S&P 500 over three months. Completion of the New Drug Application, guided on 12 November 2026 to within several weeks, and…NAVNNavanLow Navan's shares are more likely to lag the S&P 500 than lead it over three months: they closed at $26.20 on 12 November 2026, 15.2% below the August high, with no new results since September. The fiscal third-quarter report, expected around…NBTXNanobiotixLow Nanobiotix shares are more likely to lag the S&P 500 over the next three months because the Phase 3 NANORAY-312 head and neck cancer readout that decides the case has no date. Cash runs into 2029, so news on that trial's timing or result…NEXANexa ResourcesLow Nexa Resources, a zinc producer, is more likely to lag the S&P 500 over three months: its shares track Boliden's pending purchase of the controlling holder, and Citigroup cut its target to $12 on 12 November 2026. Boliden's 23 November…NGNENeurogeneLow Neurogene's Rett syndrome gene therapy NGN-401 is funded into the first quarter of 2029, but the shares are more likely to lag the S&P 500 over three months: they closed at $23.90 on 12 November 2026, through the kill line. The Embolden…NKTRNektar TherapeuticsLow Nektar Therapeutics is more likely to lag the S&P 500 over three months: the shares closed flat at $37.27 on 13 November 2026 after the third-quarter report, and alopecia durability doubts remain. The 24-week off-treatment alopecia data,…NRIXNurix TherapeuticsLow Nurix Therapeutics is more likely to lag the S&P 500 over three months: Sanofi ended its STAT6 program on 3 November 2026 and the shares are down 42.3% in three months. The bexobrutideg poster at the ASH meeting on 13 December 2026 decides…NVAXNovavaxLow Novavax raised its 2026 adjusted revenue framework to $385–415 million on 5 November 2026, but the lift is mostly the known $125 million Sanofi milestone, and the shares closed at $9.98 on 11 November 2026, below pre-report levels.…NVCRNovoCureLow NovoCure's core glioblastoma business beat and raised in the third quarter, but the FDA's 9 November 2026 Not Approvable letter for Optune Mya removes a 2027 brain-metastases launch; the outcome of the company's talks with the FDA settles…NVECNVELow NVE Corporation's shares are more likely to lag the S&P 500 over three months: September-quarter product sales of $5,575,282 were half June's $10,734,735. The fiscal third-quarter report, expected around January 2027, settles whether…OBIOOrchestra BioMed HoldingsLow Orchestra BioMed is more likely to lag the S&P 500 over three months: the BACKBEAT hypertension data that decide the case are planned for the Heart Rhythm 2027 meeting in May 2027, after that window, and the shares are up 39.5% in three…OGNOrganonLow Organon & Co. trades as a completion case on Sun Pharma's $14.00 cash acquisition; the $13.85 close on 9 November 2026 sits just under the offer, and the 3 December 2026 European Commission deadline and remaining clearances settle it.ORICOric PharmaceuticalsLow Oric Pharmaceuticals' enozertinib has a stated Phase 3 path, but the shares are more likely to lag the S&P 500 over three months: they closed at $8.50 on 12 November 2026, and third-quarter cash and dilution decide whether they recover.PAYOPayoneer GlobalLow Payoneer Global is a pending $7.40-per-share all-cash takeout by Nuvei; the shares trade just below that price, so the remaining gain is small, and regulatory clearance and completion, targeted for mid-2027, settle the case.PGENPrecigenLow Precigen's PAPZIMEOS is now profitable and cash-generating, but quarterly growth slowed to 37% and a rival RRP drug was approved, so the shares are more likely to lag the S&P 500 over three months; fourth-quarter revenue settles it.PLPlanet Labs PBCLow Planet Labs' shares are more likely to lag the S&P 500 over three months: third-quarter guidance of $101–105 million sits under consensus and contracted work is shrinking. The report after the close on 10 December 2026 settles it.PRTHPriority Technology HoldingsLow Priority Technology Holdings trades as a pending $8.05-per-share cash buyout, so upside is capped near the offer and the S&P 500 is more likely to lead; the unaffiliated-shareholder vote and regulatory approvals, guided for the first half…QSIQuantum-SiLow Quantum-Si's shares still price in more than its Proteus protein sequencer has delivered: launch is guided for Q2 2027, and 2026 revenue for about $1.0M. The company's all-20-amino-acid target, due by year-end 2026, is the next test.QUREuniQureLow uniQure's Huntington's gene therapy AMT-130 cleared the FDA filing stage with priority review and a 1 May 2027 decision date, yet the shares still closed at $22.71 on 10 November 2026; the advisory committee decides whether the weakened…RAPPRapport TherapeuticsLow Rapport Therapeutics' RAP-219 beat placebo in bipolar mania by 3.1 points, short of management's 4-point bar, but cash is guided through 2029; fourth-quarter 2026 seizure safety data decide whether tolerability concerns spread.RBLXRobloxLow Roblox Corporation beat its Q3 bookings guide ($1.697 billion) but daily users fell 9% year over year and Q4 bookings are guided down 10–15%; the Q4 report in early 2027 shows whether users stabilise.RCKTRocket PharmaceuticalsLow Rocket Pharmaceuticals' shares are more likely to lag the S&P 500 over three months: the Danon gene therapy trial reports no efficacy until mid-2028, and first KRESLADI patient onboarding, guided for the fourth quarter of 2026, is the next…RLYBRallybioLow Rallybio's stockholders approved the Avenzo Therapeutics merger on 4 November 2026 and the final cash distribution is $13.90 per share, so what remains is a roughly 2.8% stake in an early-stage oncology company. The merger closing after…RPAYRepay HoldingsLow Repay Holdings' Q3 report on 9 November 2026 beat estimates, but the core consumer segment grew 0.3% organically and growth and cash-conversion targets were cut. The 7 December 2026 Investor Day shows whether management can restore the…SAFTSafety Insurance GroupLow Safety Insurance Group's shares closed at $104.49 on 10 November 2026, below Mapfre's fixed $105.00 cash offer. Shareholders approved the deal on 3 November 2026, so Massachusetts insurance regulator approval now settles the outcome.SANASana BiotechnologyLow Sana Biotechnology's type 1 diabetes case rests on one patient's result, and the shares are more likely to lag the S&P 500 over three months; the SC451 IND filing and trial start, guided "as early as this year" on 5 November 2026, settles…SEERLow Seer, Inc. closed at $1.61 on 10 November 2026 after its board rejected both take-private proposals and the third-quarter report cut 2026 revenue guidance to $13.5-14.5 million. Cash of $198.1 million and the year-end patent ruling now…SIDUSidus SpaceLow Sidus Space is more likely to lag the S&P 500 over three months: on 12 November 2026 its restatement widened to eight reporting periods back to the third quarter of 2024, with no date for corrected filings. The third-quarter Form 10-Q, due…SITCSITE CentersLow SITE Centers, a liquidation stub after its $3.00 payout, is more likely to lag the S&P 500 over three months: it has not said what it will still distribute, and the 4 December 2026 NYSE delisting and The Blocks sale closing settle the read.SKYASkyAILow SkyAI's shares are more likely to lag the S&P 500 over three months. They closed at $2.45 on 12 November 2026, below the $3.00 cash tender that expired that night, and the untendered shares' value rests on the cash left after payment.SLDBSolid BiosciencesLow Solid Biosciences' Duchenne gene therapy SGT-003 is more likely to lag the S&P 500 over three months: the Food and Drug Administration (FDA) Type C meeting in late 2026 and its minutes decide whether accelerated approval stays open.SMTISanara MedTechLow Sanara MedTech is more likely to lag the S&P 500 over three months: its sale to MiMedx has no closing date after the FTC's 15 October 2026 Second Request, and the 12 November 2026 guidance cut weakens the fallback value. FTC clearance or a…SNDXSyndax PharmaceuticalsLow Syndax Pharmaceuticals is more likely to lag the S&P 500 over three months: Revuforj sales are growing, yet the shares are down 51.9% in three months. The frontline leukemia data at ASH on 13 December 2026 and 14 December 2026 settle it.SPRYARS PharmaceuticalsLow ARS Pharmaceuticals, a one-product company selling the needle-free epinephrine spray neffy, is more likely to lag the S&P 500 over three months: third-quarter revenue missed estimates and no new insurance coverage has arrived. The…SPSCSPS CommerceLow SPS Commerce's shares are more likely to trail the S&P 500 over the next three months: 2026 revenue guidance fell twice and the reported GTCR takeover talks remain unconfirmed. A signed deal or the 2027 outlook settles it.SRZNSurrozenLow Surrozen's cash now runs into 2029, but the shares at $31.88 already carry that news; with the resale registration for $11.60 placement stock due about 19 November 2026, they are more likely to lag the S&P 500 than lead it.SSTISoundThinkingLow SoundThinking's shares are more likely to lag the S&P 500 over three months because Transom Capital Group's $8.00-cash-plus-CVR tender offer caps the upside; the 17 November 2026 tender expiry decides whether holders receive it.STAASTAAR SurgicalLow STAAR Surgical's third-quarter report showed China demand holding up (underlying China sales +31%) but supply and gross margin still lagging; the shares closed at $23.87 on 10 November 2026, and the fourth-quarter report decides whether…STNEStoneCoLow StoneCo's shares are more likely to lag the S&P 500 over three months: its over-90-day loan-loss ratio rose to 9.92% in the third quarter and adjusted gross profit fell 8.0%, despite a raised 2026 earnings outlook. Brazil's late-January…STROSutro BiopharmaLow Sutro Biopharma's shares are more likely to lag the S&P 500 over three months: cash fell to $142.2 million at 30 September 2026, Merck ended MK-1484 on 7 November 2026, and the next STRO-004 data update is guided to the first half of 2027.SYNASynapticsLow Synaptics' shares trade as a claim on onsemi's $123.00 per share cash offer with no rival bidder left, so they are more likely to trail the S&P 500; the 17 November 2026 shareholder vote and China's antitrust review settle it.SYRESpyre TherapeuticsLow Spyre Therapeutics' shares are more likely to lag the S&P 500 over three months: its three bowel-disease antibodies cleared single-agent trials, but combination data is not due until the third quarter of 2027 and the company keeps issuing…TECHBio-TechneLow Bio-Techne's shares are more likely to lag the S&P 500 over three months: they sit just under Merck KGaA's $73.00 cash offer, which caps the gain. Receipt of the remaining regulatory approvals, guided for late 2026 or early 2027, settles…TENXTenax TherapeuticsLow Tenax Therapeutics is more likely to lag the S&P 500 over three months: its recovery needs the FDA to accept an enriched LEVEL-2 trial of TNX-103 after LEVEL failed. The undated Type C meeting outcome settles it.TLRYTilray BrandsLow Tilray Brands has narrowed its fiscal 2027 adjusted EBITDA target to $70–75 million and announced about $30 million of planned annual savings, but the shares still trade near $2.65 and second-quarter results around 8 January 2027 decide…TMCTMC the metalsLow TMC the metals company's nodule case hinges on NOAA certifying its USA-A application, which NOAA estimates for mid-December 2026; with no revenue and cash falling, the shares are more likely to lag the S&P 500 over three months until that…TNETTrinet GroupLow TriNet Group's profit recovery is intact (89% insurance cost ratio, 2026 adjusted earnings guidance raised to $5.10 a share), but worksite employees fell 11%, so the shares are more likely to lag the S&P 500 over three months;…TNGXTango TherapeuticsLow Tango Therapeutics' pancreatic-cancer combination is active, but the shares are more likely to lag the S&P 500 over three months: the 23 October 2026 ESMO update (82% response in 22 patients versus 92% in 12) did not extend June's result.…TSHATaysha Gene TherapiesLow Taysha Gene Therapies' Rett syndrome therapy TSHA-102 is more likely to lag the S&P 500 over three months; pivotal six-month interim data and FDA feedback on the filing route, guided to the first half of 2027, settle it.ULBIUltralifeLow Ultralife Corporation trades as a capped claim on EnerSys's $16.00-per-share cash offer, so it is more likely to lag the S&P 500 than lead it; US and UK clearances and the tender, first due to expire on 3 December 2026, settle whether…UTZUtz BrandsLow Utz Brands shares are more likely to lag the S&P 500 because stockholders approved Intersnack's $14.25 cash take-private on 13 November 2026 and the shares already close there; the closing expected on or around 20 November 2026 settles it.VECOVeeco InstrumentsLow Veeco Instruments' pending Axcelis merger now closes by end of Q1 2027, not 2026, and Q3 earnings missed estimates; China's SAMR ruling and the Q4 revenue guide of $230–260 million settle the case.VERIVeritoneLow Veritone's $45.58 million of convertible notes mature on 15 November 2026, and the company moved its third-quarter report to 16 November 2026 to give "material updates" on debt talks, so the shares are more likely to lag the S&P 500. A…VERULow Veru's case rests on whether its oral drug enobosarm preserves lean mass alongside semaglutide; the PLATEAU 32-week interim, guided to calendar Q1 2027, settles it, while going-concern doubt and an open stock-sale program cap the shares.VORVor BiopharmaLow Vor Biopharma's telitacicept case is more likely to lag the S&P 500 over three months: the global myasthenia gravis trial reads out in the first half of 2027, and the 12 November 2026 RC298 deal and a $150 million share filing add dilution…VREXVarex ImagingLow Varex Imaging is a deal-completion case capped at Teledyne's $18.90 cash price; the UK and US reviews ending 18 November 2026 and 19 November 2026 decide whether completion in early 2027 stays on track.VRNSVaronis SystemsLow Varonis Systems is a pending $49.75-per-share cash acquisition by Proofpoint, and the 10 November 2026 close of $49.10 sits below the offer, so upside is capped unless a rival bid appears. Stockholder approval and regulatory clearance,…VSTMVerastemLow Verastem's shares look more likely to lag the S&P 500: its KRAS G12D drug VS-7375 is funded into the first half of 2028, but ovarian revenue missed forecasts and a $100M share program adds supply. The year-end 2026 Phase 3 start and…XENEXenon PharmaceuticalsLow Xenon Pharmaceuticals' shares are more likely to lag the S&P 500 because a December 2026 depression readout under a safety overhang now outweighs its pending epilepsy filing; FDA acceptance, due about 16 November 2026, and that readout…XPLow XP Inc. is more likely to lag the S&P 500 over three months: Brazil's fiscal and rate outlook worsened after Lula's 25 October 2026 win and four brokers cut targets. The 17 November 2026 third-quarter report shows whether inflows held near…XPOFXponential FitnessLow Xponential Fitness's weak third quarter (same-store sales down 7.5%) undercuts the business behind Fund 1's $5.61–$7.00 cash proposal, so the shares are more likely to lag the S&P 500 unless the board's review yields a signed or financed…YSSYork Space SystemsLow York Space Systems' shares are more likely to lag the S&P 500: the 12 November 2026 report showed backlog of $581.0 million and a $749.7 million goodwill write-down. The fourth-quarter report in March 2027 shows whether backlog rises above…ZURAZura BioLow Zura Bio's shares are more likely to lag the S&P 500 over three months: the TibuSHIELD hidradenitis suppurativa trial failed on 9 November 2026 and the company dropped that indication. Only the systemic sclerosis result, due by mid-2027,…